Alprolix FDA Approval History
FDA Approved: Yes (First approved March 28, 2014)
Brand name: Alprolix
Generic name: coagulation factor IX (recombinant)
Company: Biogen Inc.
Treatment for: Hemophilia B
Alprolix (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.
Development timeline for Alprolix
| Date | Article |
|---|---|
| Mar 28, 2014 | Approval FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
